National Heart, Lung, and Blood Institute (NHLBI)
nhlbi.nih.govLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,137
Active
88
Phase 3
123
Total enrollment
10,852,506
Pipeline matrix
Showing 40 of 50 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Fluzone | — | — | — | — | — | 1 | |
| Shingrix | — | — | — | — | — | 1 | |
| Flucelvax | — | — | — | — | — | 1 | |
| Afluria | — | — | — | — | — | 1 | |
| PREVNAR 13 | — | — | — | — | — | 1 | |
| Heplisav -B | — | — | — | — | — | 1 | |
| Pfizer-COVID-19 Vaccine | — | — | — | — | — | 1 | |
| FluLaval | — | — | — | — | — | 1 | |
| Fluarix | — | — | — | — | — | 1 | |
| PNEUMOVAX 23 | — | — | — | — | — | 1 | |
| PREVNAR 20 | — | — | — | — | — | 1 | |
| AREXVY, ABRYSVO | — | — | — | — | — | 1 | |
| [18F]FAPI-74 | — | — | — | — | — | 1 | |
| Sirolimus | — | — | — | — | — | 7 | |
| Cyclophosphamide | — | — | — | — | 16 | ||
| Alemtuzumab | — | — | — | — | — | 10 | |
| Filgrastim | — | — | — | — | — | 4 | |
| Eltrombopag | — | — | — | — | — | 7 | |
| Pentostatin | — | — | — | — | — | 3 | |
| Abatacept | — | — | — | — | — | 2 | |
| briquilimab | — | — | — | — | — | 2 | |
| Hydroxyurea | — | — | 10 | ||||
| Cyclosporine | — | — | — | — | 15 | ||
| Fludarabine | — | — | — | — | — | 7 | |
| Ibrutinib | — | — | — | — | — | 3 | |
| Ruxolitinib | — | — | — | — | — | 2 | |
| Plerixafor | — | — | — | — | 2 | ||
| During Venetoclax | — | — | — | — | — | 1 | |
| Omidubicel | — | — | — | — | — | 1 | |
| Baricitinib | — | — | — | — | — | 1 | |
| Mitapivat | — | — | — | — | — | 1 | |
| Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 | — | — | — | — | — | 1 | |
| Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 | — | — | — | — | — | 1 | |
| Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 | — | — | — | — | — | 1 | |
| Extension Cohort | — | — | — | — | — | 1 | |
| Horse-Anti-thymocyte-Globulin | — | — | — | — | — | 1 | |
| PCI 32765 | — | — | — | — | — | 1 | |
| control olive oil | — | — | — | — | — | 1 | |
| palmitoleate-rich oil | — | — | — | — | — | 1 | |
| albuterol inhaler | — | — | — | — | — | 1 |
10 more active programs hidden
Next readouts
- 2014-06-20
- 2018-01-30
- 2018-08-01
- 2019-10-02
- 2023-07-27
- 2023-10-31
- 2023-12-31
- 2024-12-18
- 2025-07-22
- 2025-08-01
Top conditions
- Cardiovascular Diseases457
- Heart Diseases438
- Coronary Disease192
- Hypertension157
- Lung Diseases109
- Asthma75
- Atherosclerosis75
- Obesity73
Frequently asked questions about National Heart, Lung, and Blood Institute (NHLBI)
- How many clinical trials does National Heart, Lung, and Blood Institute (NHLBI) have on ClinicalTrials.gov?
- National Heart, Lung, and Blood Institute (NHLBI) is listed as the lead sponsor on 1,137 clinical trials in ClinicalTrials.gov, 88 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Heart, Lung, and Blood Institute (NHLBI)'s trials are in Phase 3?
- 123 of National Heart, Lung, and Blood Institute (NHLBI)'s trials are in Phase 3, spread across 50 active drug programs.
- What therapeutic areas does National Heart, Lung, and Blood Institute (NHLBI) focus on?
- National Heart, Lung, and Blood Institute (NHLBI)'s most-studied conditions on ClinicalTrials.gov are Cardiovascular Diseases, Heart Diseases, Coronary Disease, Hypertension, Lung Diseases.
- When are National Heart, Lung, and Blood Institute (NHLBI)'s next clinical trial readouts?
- National Heart, Lung, and Blood Institute (NHLBI) has 10 upcoming primary-completion readouts tracked here; the soonest is “PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma”, expected around 2014-06-20.